Johnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.
Follow JNJ
Johnson & Johnson (JNJ) Return on equity
Johnson & Johnson's return on equity over the twelve months to 30 September 2026 was 0.00%, down 35.0 percentage points from fiscal 2025 (35.0%). Over the past ten years it has ranged from 0.00% (fiscal 2015) to 48.3% (fiscal 2023); the current reading is higher than 91% of that period. That is below the Drug Manufacturers General industry median of 5.87% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 35.0% | 14.97 |
| FY2024 | 20.1% | (28.23) |
| FY2023 | 48.3% | 24.50 |
| FY2022 | 23.8% | (6.62) |
| FY2021 | 30.4% | 6.44 |
| FY2020 | 24.0% | (1.39) |
| FY2019 | 25.4% | (0.15) |
| FY2018 | 25.5% | 23.52 |
| FY2017 | 1.99% | (21.61) |
| FY2016 | 23.6% | 23.60 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LLY Eli Lilly and Company compare | 102.3% |
| AMGN Amgen Inc. compare | 91.5% |
| NVS Novartis AG compare | 30.4% |
| AZN AstraZeneca PLC compare | 22.0% |
| MRK Merck & Co., Inc. compare | 6.97% |
| PFE Pfizer Inc. compare | 4.97% |
| JNJ Johnson & Johnson | 0.00% |
| GILD Gilead Sciences, Inc. compare | −20.7% |
| ABBV AbbVie Inc. compare | −208.1% |
| Drug Manufacturers General industry median | 5.87% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on JNJ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement